Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer-Clinical Notice
暂无分享,去创建一个
Anthony Rhodes | Paul Valenstein | Daniel F. Hayes | Keith Miller | Sheila Taube | Lisa McShane | Antonio C. Wolff | Thomas Wheeler | Mitch Dowsett | Richard Love | Hironobu Sasano | James L. Wittliff | Sunil Badve | David G. Hicks | Soonmyung Paik | D. Craig Allred | M. Dowsett | D. Visscher | M. Hammond | S. Paik | L. McShane | A. Wolff | T. Wheeler | S. Badve | G. Viale | D. Allred | D. Hayes | C. Osborne | H. Sasano | S. Lester | R. Love | P. Fitzgibbons | J. Perlmutter | E. Torlakovic | J. Wittliff | F. Sweep | S. Taube | K. Hagerty | G. Francis | N. Goldstein | M. Hayes | D. Hicks | P. Mangu | K. Miller | A. Rhodes | J. Schwartz | P. Valenstein | R. B. Williams | Giuseppe Viale | Jane Perlmutter | Malcolm Hayes | C. Kent Osborne | M. Elizabeth H. Hammond | Daniel Visscher | Glenn Francis | Susan Lester | Emina Emilia Torlakovic | Jared N. Schwartz | Karen L. Hagerty | Patrick L. Fitzgibbons | Neil S. Goldstein | Pamela B. Mangu | Fred C. G. Sweep | R. Bruce Williams
[1] C. Jordan. Historical perspective on hormonal therapy of advanced breast cancer. , 2002, Clinical therapeutics.
[2] J. Cuzick,et al. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] B. Reid,et al. Oestrogen receptor in breast cancer: prognostic studies using a new immunohistochemical assay , 1990, Histopathology.
[4] M. Ellis,et al. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. , 2009, JAMA.
[5] J. Ioannidis,et al. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. , 2006, Journal of the National Cancer Institute.
[6] P. Neven,et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] E. Mallon,et al. Adjuvant ovarian ablation vs CMF chemotherapy in premenopausal breast cancer patients: trial update and impact of immunohistochemical assessment of ER status. , 2002, Breast.
[8] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.
[9] E B Cox,et al. Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. , 1986, Cancer research.
[10] A. Scharl,et al. Immunohistochemical detection of progesterone receptor in formalin-fixed and paraffin-embedded breast cancer tissue using a monoclonal antibody , 2006, Archives of Gynecology and Obstetrics.
[11] V. McCormack,et al. Sex steroids, growth factors and mammographic density: a cross-sectional study of UK postmenopausal Caucasian and Afro-Caribbean women , 2009, Breast Cancer Research.
[12] D. DeMets,et al. Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] R. Gelber,et al. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. , 2006, Journal of the National Cancer Institute.
[14] H. Müller-Hermelink,et al. Tissue array technology for testing interlaboratory and interobserver reproducibility of immunohistochemical estrogen receptor analysis in a large multicenter trial. , 2002, American journal of clinical pathology.
[15] B. Kennedy,et al. Massive estrogen administration in premenopausal women with metastatic breast cancer , 1962, Cancer.
[16] C. Redmond,et al. Treatment of primary breast cancer with chemotherapy and tamoxifen. , 1981, The New England journal of medicine.
[17] T. Kuopio,et al. Immunohistochemical staining of estrogen and progesterone receptors: aspects for evaluating positivity and defining the cutpoints. , 2005, Anticancer research.
[18] C. Adebamowo,et al. Immunohistochemical and molecular subtypes of breast cancer in Nigeria , 2008, Breast Cancer Research and Treatment.
[19] J M Esteban,et al. Quantitative immunohistochemical assay for hormonal receptors: technical aspects and biological significance. , 1994, Journal of cellular biochemistry. Supplement.
[20] D. Allred,et al. Development of Standard Estrogen and Progesterone Receptor Immunohistochemical Assays for Selection of Patients for Antihormonal Therapy , 2007, Applied immunohistochemistry & molecular morphology : AIMM.
[21] Predicting response to endocrine therapy in human breast cancer: a hypothesis. , 1976, Science.
[22] J. Wittliff,et al. Establishment of uniformity in steroid receptor analyses used in cooperative clinical trials of breast cancer treatment. , 1980, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[23] S. Edge,et al. Prognostic factors in breast cancer , 2005 .
[24] E. Jensen,et al. Estrogen-receptor interactions in target tissues. , 1967, Archives d'anatomie microscopique et de morphologie experimentale.
[25] Karen A Gelmon,et al. Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] W. McGuire,et al. Therapy for cancer of the breast. Current status of steroid hormone receptors. , 1979, The Western journal of medicine.
[27] B. Jasani,et al. Potential for false-positive staining with a rabbit monoclonal antibody to progesterone receptor (SP2): findings of the UK National External Quality Assessment Scheme for Immunocytochemistry and FISH highlight the need for correct validation of antibodies on introduction to the laboratory. , 2008, American journal of clinical pathology.
[28] W. McGuire,et al. The value of estrogen and progesterone receptors in the treatment of breast cancer , 1980, Cancer.
[29] R. Bast,et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] Clive R Taylor,et al. Consensus Recommendations on Estrogen Receptor Testing in Breast Cancer By Immunohistochemistry , 2008, Applied immunohistochemistry & molecular morphology : AIMM.
[31] D. Barnes,et al. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems , 2000, Journal of clinical pathology.
[32] D. Oxley,et al. Precision in estrogen and progesterone receptor assays. Results of the first CAP pilot survey. , 1982, American journal of clinical pathology.
[33] A. Trentham-Dietz,et al. Differences in breast cancer risk factors by tumor marker subtypes among premenopausal Vietnamese and Chinese women. , 2005, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[34] Jingqin Luo,et al. Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics , 2008, Journal of the National Cancer Institute.
[35] J. Ferlay,et al. Globocan 2000 : cancer incidence, mortality and prevalence worldwide , 2001 .
[36] B. Djulbegovic,et al. Comparison of sex steroid receptor determinations in human breast cancer by enzyme immunoassay and radioligand binding , 1990, Journal of clinical laboratory analysis.
[37] M. Cronin,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.
[38] W. McGuire,et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] E B Cox,et al. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. , 1985, Archives of pathology & laboratory medicine.
[40] Jack Cuzick,et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] D. Hayes. Markers of endocrine sensitivity , 2008, Breast Cancer Research.
[42] D. Arber. Effect of Prolonged Formalin Fixation on the Immunohistochemical Reactivity of Breast Markers , 2002, Applied immunohistochemistry & molecular morphology : AIMM.
[43] N. Sneige,et al. Estrogen Receptor Analysis for Breast Cancer: Current Issues and Keys to Increasing Testing Accuracy , 2005, Advances in anatomic pathology.
[44] Maria Sjöberg,et al. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. , 2005, Molecular endocrinology.
[45] R. Gelber,et al. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] M. Lippman. An assessment of current achievements in the systemic management of breast cancer , 1984, Breast Cancer Research and Treatment.
[47] M. Hammond,et al. Recommendations for validating estrogen and progesterone receptor immunohistochemistry assays. , 2010, Archives of pathology & laboratory medicine.
[48] G. Anderson,et al. Expanding priorities--confronting chronic disease in countries with low income. , 2007, The New England journal of medicine.
[49] N. Goldstein,et al. Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. , 2003, American journal of clinical pathology.
[50] Edith A Perez,et al. Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] D. Horsfall,et al. A simple index using video image analysis to predict disease outcome in primary breast cancer , 1999, International journal of cancer.
[52] G. Wilding,et al. Delay to formalin fixation effect on breast biomarkers , 2009, Modern Pathology.
[53] K. Jirström,et al. High Progesterone Receptor Expression Correlates to the Effect of Adjuvant Tamoxifen in Premenopausal Breast Cancer Patients , 2006, Clinical Cancer Research.
[54] M. Dowsett,et al. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[55] I. Ferri,et al. Computer-assisted immunocytochemical determination of breast cancer steroid receptors. Frozen sections vs paraffin sections. , 2001, Breast.
[56] H. Yamashita,et al. Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer , 2006, Breast cancer.
[57] V. Jensen,et al. Immunohistochemical quantitation of oestrogen receptors and proliferative activity in oestrogen receptor positive breast cancer. , 1995, Journal of clinical pathology.
[58] C K Osborne,et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] A. Gown,et al. Unmasking the mysteries of antigen or epitope retrieval and formalin fixation. , 2004, American journal of clinical pathology.
[60] J. Yahalom,et al. [Treatment of metastatic breast cancer]. , 1986, Harefuah.
[61] Norman Wolmark,et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. , 2006, JAMA.
[62] W. McGuire. Estrogen receptors in human breast cancer. , 1973, The Journal of clinical investigation.
[63] G. Francis,et al. Frequency and reliability of oestrogen receptor, progesterone receptor and HER2 in breast carcinoma determined by immunohistochemistry in Australasia: results of the RCPA Quality Assurance Program , 2007, Journal of Clinical Pathology.
[64] S. Martino,et al. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand‐binding assay compared with ER, PgR and pS2, by immuno‐histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group study , 2000, International journal of cancer.
[65] C. Meijer,et al. Estrogen receptors in human breast cancer , 1982 .
[66] K. Hirakawa,et al. Immunohistochemical assessment for estrogen receptor and progesterone receptor status in breast cancer: Analysis for a cut-off point as the predictor for endocrine therapy , 2004, Breast cancer.
[67] C. Redmond,et al. Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[68] R M Levenson,et al. Quantification of immunohistochemistry—issues concerning methods, utility and semiquantitative assessment II , 2006, Histopathology.
[69] A. Haddow,et al. Influence of Synthetic Oestrogens on Advanced Malignant Disease , 1944, British medical journal.
[70] I. Nenci,et al. Detection and dynamic localisation of estradiol-receptor complexes in intact target cells by immunofluorescence technique. , 1976, Journal of steroid biochemistry.
[71] D. Barnes,et al. Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening , 2000, Journal of clinical pathology.
[72] W. McGuire,et al. Progesterone receptors as a prognostic factor in stage II breast cancer. , 1983, The New England journal of medicine.
[73] Y Wang,et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.
[74] M. Werner,et al. Influence of Fixation, Antibody Clones, and Signal Amplification on Steroid Receptor Analysis , 1998 .
[75] R. Gelber,et al. Facilitating consensus by examining patterns of treatment effects. , 2009, Breast.
[76] W. McGuire,et al. Hormone receptors in primary and advanced breast cancer. , 1980, Clinics in endocrinology and metabolism.
[77] M. Dowsett,et al. A randomised study of the effects of letrozole and anastrozole on oestrogen receptor positive breast cancers in postmenopausal women , 2009, Breast Cancer Research and Treatment.
[78] C. Osborne,et al. HER-2 Amplification, HER-1 Expression, and Tamoxifen Response in Estrogen Receptor-Positive Metastatic Breast Cancer , 2004, Clinical Cancer Research.
[79] D. Barnes,et al. Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. , 1996, British Journal of Cancer.
[80] D. Allred,et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study , 2004, Modern Pathology.
[81] R. Schiff,et al. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. , 2008, Cancer research.
[82] R. Gelman,et al. Estrogen receptor assay: interlaboratory and intralaboratory variations in the measurement of receptors using dextran-coated charcoal technique: a study sponsored by E.C.O.G. , 1981, European journal of cancer.
[83] B. Rasmussen,et al. Prognostic usefulness of estrogen receptor immunocytochemical assays for human breast cancer. , 1986, Cancer research.
[84] L. Rogers,et al. Fixation time does not affect expression of HER2/neu: a pilot study. , 2010, American journal of clinical pathology.